» Articles » PMID: 23288422

Chimpanzee GB Virus C and GB Virus A E2 Envelope Glycoproteins Contain a Peptide Motif That Inhibits Human Immunodeficiency Virus Type 1 Replication in Human CD4⁺ T-cells

Overview
Journal J Gen Virol
Specialty Microbiology
Date 2013 Jan 5
PMID 23288422
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

GB virus type C (GBV-C) is a lymphotropic virus that can cause persistent infection in humans. GBV-C is not associated with any disease, but is associated with reduced mortality in human immunodeficiency virus type 1 (HIV-1)-infected individuals. Related viruses have been isolated from chimpanzees (GBV-Ccpz) and from New World primates (GB virus type A, GBV-A). These viruses are also capable of establishing persistent infection. We determined the nucleotide sequence encoding the envelope glycoprotein (E2) of two GBV-Ccpz isolates obtained from the sera of captive chimpanzees. The deduced GBV-Ccpz E2 protein differed from human GBV-C by 31 % at the amino acid level. Similar to human GBV-C E2, expression of GBV-Ccpz E2 in a tet-off human CD4(+) Jurkat T-cell line significantly inhibited the replication of diverse HIV-1 isolates. This anti-HIV-replication effect of GBV-Ccpz E2 protein was reversed by maintaining cells in doxycycline to reduce E2 expression. Previously, we found a 17 aa region within human GBV-C E2 that was sufficient to inhibit HIV-1. Although GBV-Ccpz E2 differed by 3 aa differences in this region, the chimpanzee GBV-C 17mer E2 peptide inhibited HIV-1 replication. Similarly, the GBV-A peptide that aligns with this GBV-C E2 region inhibited HIV-1 replication despite sharing only 5 aa with the human GBV-C E2 sequence. Thus, despite amino acid differences, the peptide region on both the GBV-Ccpz and the GBV-A E2 protein inhibit HIV-1 replication similar to human GBV-C. Consequently, GBV-Ccpz or GBV-A infection of non-human primates may provide an animal model to study GB virus-HIV interactions.

Citing Articles

Downregulation of Cytokines and Chemokines by GB Virus C After Transmission Via Blood Transfusion in HIV-Positive Blood Recipients.

Lanteri M, Vahidnia F, Tan S, Stapleton J, Norris P, Heitman J J Infect Dis. 2014; 211(10):1585-96.

PMID: 25425697 PMC: 4481614. DOI: 10.1093/infdis/jiu660.

References
1.
Bhattarai N, Stapleton J . GB virus C: the good boy virus?. Trends Microbiol. 2012; 20(3):124-30. PMC: 3477489. DOI: 10.1016/j.tim.2012.01.004. View

2.
Xiang J, George S, Wunschmann S, Chang Q, Klinzman D, Stapleton J . Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet. 2004; 363(9426):2040-6. DOI: 10.1016/S0140-6736(04)16453-2. View

3.
Polgreen P, Xiang J, Chang Q, Stapleton J . GB virus type C/hepatitis G virus: a non-pathogenic flavivirus associated with prolonged survival in HIV-infected individuals. Microbes Infect. 2003; 5(13):1255-61. DOI: 10.1016/j.micinf.2003.08.006. View

4.
Birkenmeyer L, Desai S, Muerhoff A, Leary T, Simons J, Montes C . Isolation of a GB virus-related genome from a chimpanzee. J Med Virol. 1998; 56(1):44-51. DOI: 10.1002/(sici)1096-9071(199809)56:1<44::aid-jmv8>3.0.co;2-n. View

5.
Herrera E, Gomara M, Mazzini S, Ragg E, Haro I . Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide. J Phys Chem B. 2009; 113(20):7383-91. DOI: 10.1021/jp900707t. View